Bedrocan grows standardised cannabis cultivars with a consistent composition of cannabinoids and terpenes. Our cannabis products are independently tested for desired properties by specialised laboratories. Because of its pharmaceutical quality, and the possibility to export these products, many scientists have chosen to work with Bedrocan to undertake scientific studies and clinical research projects. Click here for a study overview of Bedrocan products used in humans.
Bedrocan accounts for a wide range of (potentially) active components in our plants. By visualising up to 30 different cannabinoids and terpenes, we aim to reduce the endless number of popular varieties (also named cultivars) to a manageable, chemically distinct set of varieties (or chemovars). The products currently available through Bedrocan are listed below.
Introduced in 2003, Bedrocan® is the brand name for the sativa cultivar Cannabis sativa L. ‘Afina’.
Cannabis sativa L. ‘Afina’ is the first cultivar developed and it features 22% THC, with a CBD-level below 1%. It’s the most widely used medicinal cannabis product and has been used in more research than other products.
Bedrocan® is available in flos form.
Introduced in 2005, Bedrobinol® is the brand name for the sativa cultivar Cannabis sativa L. ‘Ludina’.
Cannabis sativa L. ‘Ludina’ is bred in-house by Bedrocan. Its THC-level can be considered medium strength, standardised at 13,5%, with a CBD-level below 1 %.
Bedrobinol® is available in flos form.
Introduced in 2007, Bediol® is the brand name for the sativa cultivar Cannabis sativa L. ‘Elida’.
Cannabis sativa L. ‘Elida’ is one of the first cannabis cultivars developed specifically to have a higher CBD content. The effects of CBD are distinctly different from THC.
Bediol® has a balanced ratio of THC 6.3% and CBD 8%. Because it is easily tolerated, physicians often prescribe Bediol® for patients who previously have not used cannabis as a medicine. The ‘Elida’ cultivar was bred in-house by Bedrocan, specifically to meet the needs of patients.
Bediol® is available in granular form.
Introduced in 2011, Bedica® is the brand name for the indica cultivar Cannabis sativa L. ‘Talea’.
Cannabis sativa L. ‘Talea’ was developed in response to mounting evidence of a real difference in the effects of sativa and indica types.
Characteristic differences between indica and sativa cultivars can be found in the presence of aromatic compounds (terpenes) in the plant. Bedica® contains a high amount of the myrcene terpene, which is known to have a calming effect.
Bedica® contains 14% THC with less than 1% CBD.
Bedica® is available in granular form.
Introduced in 2014, Bedrolite® is the brand name for the sativa cultivar Cannabis sativa L. ‘Rensina’.
Cannabis sativa L. ‘Rensina’ is a so-called CBD-only product, with less than 1% THC and 9% CBD. The virtual absence of THC means it does not have psychoactive properties. Bedrolite® has become the preferred choice of a number of patients with severe, intractable (untreatable) forms of epilepsy.
Bedrolite® is available in granular form.